BeiGene, Ltd., a global biotechnology firm, is making impressive strides in the field of oncology medicine. The company's array of products includes BRUKINSA, a treatment for various blood cancers, Tislelizumab, which treats solid tumor and blood cancers, and REVLIMID, a multiple myeloma treatment. BeiGene, Ltd. is also developing a number of promising drugs to treat cancer and inflammation, including Zanubrutinib, Ociperlimab, and BGB-23339. The company has forged successful collaborations with key players in the pharmaceutical industry, including Amgen, Novartis, and Bristol Myers Squibb. Enlivex Therapeutics Ltd., Shoreline Biosciences, and EUSA Pharma are also among the companies partnering with BeiGene, Ltd. to further advance the development of new oncology medicines. Despite being established as recently as 2010 and headquartered in the Cayman Islands, BeiGene, Ltd. has positioned itself as a dynamic force in the oncology medicine sector. Its ambitious product pipeline and strategic partnerships make it a company to watch.
BeiGene, Ltd.'s ticker is BGNE
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 1001-5000 employees working at BeiGene, Ltd.
It is https://www.beigene.com/
BeiGene, Ltd. is in the Healthcare sector
BeiGene, Ltd. is in the Biotechnology industry
The following five companies are BeiGene, Ltd.'s industry peers: